38results about How to "No vascular irritation" patented technology

There is provided an injection with torasemide as the main active ingredient in the invention, the preparing method of the injection is also included in the invention. The stability of the injection in the invention has been greatly improved. There is solubilizing agent and stabilizer in the preparation, the pH value is 9.0 or larger. The preparing method includes the following steps: adding 1-50% (by weight) of solubilizing agent to certain amount of injecting water; adding torasemide to the water, after it is completely dissolved, adding 0.1-5% part of stabilizer; adding water to requested amount and stirring uniformly; adding activated char to adsorb for 30min at high temperature; decarbonizing and filtering; adding medically used alkali to regulate the ph value to 9.0 or larger; aseptically filtering; after the assay is approved, packaging, degerming and stocking. The advantages of the invention include: high stability, short preparing time, low cost, no haemolyticus, blood vessel stimulus and allerfic response, low growing speed of relative substances.

The invention provides voriconazole phosphate ester for injection and a medicinal salt thereof and a preparation method for the voriconazole phosphate ester for injection and the medicinal salt thereof. The preparation method comprises the following steps: adding 5 to 98 percent water for injection in a liquid preparation container; adding 90 to 110 percent of the accurate formula dosage of voriconazole phosphate ester and the medicinal salt thereof in the container; stirring the mixture; slowly dropwise adding a pH value regulator; regulating pH to between 6.0 and 11; supplementing water to the full dosage and then adding 0.01 to 1.0 percent (weight in volume) medicinal carbon into the product; stirring the mixture for 15 to 60 minutes; using a sand filter stick to carry out rough filtration and decarburization on the obtained product, and using a 0.22mum millipore filter to carry out fine filtration on the product until the clarity is qualified; after determining that the content of the midbody is qualified, determining the filling quantity and subpackaging the finished product in the vial; adding the semi-plug; carrying out freezing and drying on the sample; controlling the moisture content between 1 and 8 percent; pressing the plug; and carrying out capping.

The invention relates to the organic amine salt or hydrate for ceph compound used for treating bacteria infection, and the chemical formula is demonstrated in (I).Said organic amine can be lycine, arginine, tert-butylamine, diethanolamine, triethanolamine, diethylamine or meglumine. It comprises cefuroxime organic amine salt, ceftriaxone organic amine salt, ceftezole organic amine salt, cefoperazone organic amine salt, cephalothin organic amine salt, cefotaxime organic amine salt, cefradine organic amine salt, cefonicid organic amine salt, cefmetazole organic amine salt, cefodizime organic amine salt, cefmenoxime organic amine salt, ceftizoxime organic amine salt, cefpiramide organic amine salt, cefazolin organic amine salt, cefoxitinorganic amine salt and flomoxef organic amine salr. The invention provides the medical compound taking compound in formula (I) as active element and its application to preparation of medicine for treating bacteria infection.

The invention provides moxifloxacin hydrochloride glucose injection and a preparation method and use thereof. The method for preparing the injection comprises the following steps of: adding water for injection accounting for 20 to 98 percent of the batch volume into an ingredient tank, and adding glucose, a metal complexing agent and the moxifloxacin hydrochloride in a ratio; after stirring to fully dissolve the components, regulating the pH value to between 4.0 and 4.5 by using 1mol / L hydrochloric acid solution or 1mol / L sodium hydroxide, adding medicinal carbon accounting for 0.05 percent (W / V) of the total volume, uniformly stirring, maintaining the temperature of between 70 and 80 DEG C for 20 minutes, and performing circular filtering for over 20 minutes; replenishing the water for injection to the batch scale, stirring for 5 to 10 minutes, and detecting the pH value of the prepared solution (controlling to between 4.0 and 4.5); after determining that no residual water is present in an elevated tank and a pipeline, opening a valve of the elevated tank, and sampling liquid medicament at a self-circulation pipeline sampling port after the liquid medicament circulates for 20 minutes through a filter element and the elevated tank; detecting according to the intermediate quality standard, requiring that the content of the moxifloxacin hydrochloride is between 1.52 and 1.68 mg / ml, the glucose content is between 47.5 and 52.5 mg / ml, and the pH value is between 4.0 and 4.5; after the intermediate is detected to be qualified, beginning to fill; and conveying the filled semi-finished products into a sterilizing cabinet for sterilization, wherein the sterilization condition is to sterilize for 8 to 30 minutes at 121 DEG C through thermal pressure steam.

The present invention relates to new preparation form of Tirofiban, especially Tirofiban powder for injection, as antiplatelet medicine and its preparation process. The powder for injection consists of Tirofiban as active component, freeze drying support agent and pH buffering agent. The present invention expands the administration range of Tirofiban and raises the clinical administration level of Tirofiban.

The invention relates to a freeze-drying composition of a posaconazole prodrug and a preparation method and application of the freeze-drying composition of the posaconazole prodrug. The freeze-drying composition has the advantages that the freeze-drying composition is high in water solubility, and safety of the freeze-drying composition is guaranteed due to the fact that cyclodextrins auxiliary materials need not to be added during the preparation of the freeze-drying composition; the freeze-drying composition is suitable for being used for treating various amphotericin-intolerant or refractory adult invasive fungal infections; the freeze-drying composition is used as a preventive drug for high-risk patients, the freeze-drying composition is applicable to patients above 13 years old and with impaired immunity and especially applicable to patients who have graft versus host disease (GVHD) after hematopoietic stem cell transplant, patients with leukemia and patients with long-term leukopenia due to chemotherapy; compared with control drugs such as fluconazole and itraconazole, the freeze-drying composition can effectively prevent invasive aspergillosis and can lower the mortality related to the invasive fungal infections.

A polyene phosphatidylcholine liposome with high curative effect is prepared through dissolving polyene phosphatifylcholine, phosphatide and cholesterol in organic solvent, constant-temp drying for removing solvent, filming, adding vitamin, stabilizer and mannitol or glucose solution, dissolving, ultrasonic vibration or homogenizing, filtering by membrane for removing bacteria, loading in containers, filling N2 or H2 and sealing.

The present invention relates to a high-concentration-type water soluble vitamin used for intravenous injections, with each bottle containing 6.2 +-1.6 mg aneurine mononitrate, 9.8+-2.5 mg lactoflavin sodium phosphate, 80+-20 mg nicotinic amide, 9.8+-2.5 mg phosphopyridoxamine, 33.0+-8.3 mg panthoject, 200+-50 mg vitamin, 120 +-30 mu g biotin, 0.8+-0.2 mg acidum folicum, 10.0+-2.5 mu g vitamin B12 and 1-6ml water for injection. The preparing method is as follows: stirring the components mentioned above with water for injection until they are entirety dissolved, freezing-drying them in a freezing-drying machine, pressing them to prepare the water soluble vitamins used for intravenous injection. The water soluble vitamins used for intravenous injection in accordance with the present invention can be used for guarding against and curing cacotrophia caused by deficiency of water soluble vitamins and for auxiliary cure of chronic diseases such as chronic hepatic disease and the like; the water soluble vitamins used for intravenous injection possesses advantages of rapid vitamin supplying, medicament curative effect enhancement, reduced side-effects and the like, can satisfy clinical require for supplying of serious water soluble vitamins deficiency caused by diseases.

The invention discloses a Pidumode injection, which is characterized by the following: producing solution agent with Pidumode medicine and medicinal carrier; adjusting pH value at 6. 0-8. 0; setting volume of each packing unit at 2-500ml; incorporating 100-800mg Pidumode; forming salt with Pidumode and caustic soda; possessing good water-solubility and medicinal crop with the same as Pidumode; easy-degrading to aminoglutaric acid and thiazolidinecarboxylic acid with Pidumode; adjusting the pH value of the solution to near neutral; stabilizing the quality of product. This invention can be used to intravenous injection.

The invention relates to moxifloxacinhydrochloride sodium chloride injection. The injection comprises the following components in percentage by weight / volume: 0.03 to 1 percent of moxifloxacinhydrochloride, 0.01 to 3 percent of weak acid, 0.01 to 3 percent of salt of weak acid, 0.01 to 3 percent of phosphoric acid, 0.01 to 3 percent of amino acid or phosphate and 0.65 to 0.95 percent of sodium chloride.

The invention discloses an antihypertensive drug fat milk injection and a preparation method thereof. The antihypertensive drug fat milk injection is a clevidipine butyrate fat milk injection and contains clevidipine butyrate and a pharmacologically acceptable medical excipient; the medical excipient comprises an oil-phase medium, an emulsifier, an osmotic pressure regulator, a stabilizer, a metalcheating agent, a pH value regulator and injection water. The antihypertensive drug fat milk injection has stable quality and high safety and is not irritant to blood vessels.

The invention relates to a pharmaceutical composition for treating bone diseases, an injection thereof and preparation methods thereof. The pharmaceutical composition is composed of an extraction liquid of pig four limbs and a melon seed extraction liquid. Further, the pharmaceutical composition is added with mixed extraction liquids respectively prepared from commen bomhax flower, flos buddlejae and herba eupatorii. The prepared pharmaceutical composition has substantially improved treatment effect on rheumatoid arthritis, degenerative osteoarthritis, ankylosing spondylitis, sciatica, lumbar disc herniation and other bone diseases, is improved in treatment effect on gout and has no toxic and side effects. Additionally, the provided injection has extremely high stability and is substantial in effect.

The invention discloses a docetaxel freeze-dried microemulsion preparation and a preparation method thereof. The docetaxel freeze-dried microemulsion preparation comprises the following raw materials by weight: 0.05-5 parts of docetaxel, 0.1-40 parts of an oil phase, 5-30 parts of a surfactant, 0-40 parts of a cosurfactant, 5-85 parts of a hydrophilic phase, 0-15 parts of a cosolvent, 0-5 parts of an antioxidant, and 1-40 parts of a freeze-drying protective agent. Specifically, the surfactant is one or several of polyethylene glycol-8-caprylin / caprin, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, poloxamer, polyethylene glycol-12-hydroxystearate, polyethylene glycol stearate 15 and sorbitan monooleate. The preparation method includes: preparing the raw materials into a microemulsion according to the ratio, and then conducting freeze-drying. Before clinical use, the docetaxel freeze-dried microemulsion preparation has no need for a tedious two-step dilution process, after redissolving, the docetaxel freeze-dried microemulsion preparation can be subjected to intravenous injection, and has no vascular irritation and small allergic reaction. Hemolytic experiments show that the docetaxel freeze-dried microemulsion preparation does not generate hemolysis.

The invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises an amino acid sequence shown in SEQ ID NO. 1. The application also provides nucleic acids encoding the chimeric antigen receptor, vectors comprising the nucleic acids, immune effector cells comprising the chimeric antigen receptor, the nucleic acid molecules and / or the vectors, methods of preparing the immune effector cells, compositions comprising the immune effector cells, and uses of the chimeric antigen receptor.

The invention discloses a pehanorm salt or hydrate with chemical formula as picture (1) and drug composition and application to treat bacterial infection, which comprises the following parts: cefuroxime oxtatromethane, cepham qusong tromethane, cepham thiotepa tromethane, cefoperazone tromethane, cephalothin tromethane, cefotaxime tromethane, cefolading tromethane, cefonixin tromethane, cefameizin tromethane, cefadizine tromethane, cefuroxime tromethane, cefazolin tromethane, cefapamine tromethane, cefazoline tromethane, cefaadid tromethane, cefaoxofluoride tromethane, cefaminol tromethane and their hydrate.

The invention provides an ibuprofen sodium chloride injection preparation with pH of 6.0-6.5, and a preparation method thereof. The injection contains 1-10 mg / ml of ibuprofen, and injection water, wherein the pH is adjusted to 6.0-6.5 by an acid-base modifier; the dosage of the required acid-base modifier accounts for about 2-6% by weight / volume of the injection; the sodium chloride content of an isoosmotic adjusting agent is 0.70-0.90% by weight / volume. The preparation technology comprises the following steps: firstly, dissolving the acid-base modifier and the ibuprofen; adding the injection water to 20% of total mass; adding sodium chloride to stir and dissolve; adding activated carbon, filtering and decarburizing; adding water to 90% of total mass, adjusting the pH to 6.0-6.5, and adding water to total mass; filtering by 0.45 microns and 0.22 microns of microfiltration membranes; and filling and sealing and sterilizing at 121 DEG C for 8-20 minutes.

The present invention belongs to the field of medicine technology, and is especially one kind of medicine composition for treating cardiac and cerebral vascular diseases and its preparations and preparation process. The medicine composition consists of rhodiola root in 300-1800 weight portions, preferably 1000 weight portions, or its extract, and puerarin in 30-500 weight portions, preferably150 weight portions. The composition may be prepared into different pharmaceutically acceptable forms, preferably injection. The composition has synergistic effect and high stability.

The invention provides a ketoprofen intravenous administration preparation and a preparation method thereof. The injection contains 0.4mg / ml-4mg / ml ibuprofen, an alkali modifier in the amount required for adjusting pH to 6.5-9.0, 0.70%-0.90% w / v sodium chloride and water for injection.

The invention discloses an aescine A injection. The aescine A injection comprises aescine A and amino acid at the weight ratio of 10-50 to 1-10. The invention also discloses a preparation method for the injection. Compared with the prior art, the aescine A injection has stronger anti-inflammatory effect and anti-effusion activity, and lower vascular irritation and liver and kidney toxicity.

The invention relates to propofol phosphate for injection, pharmaceutical salt thereof and a preparation method thereof. The preparation method comprising the following steps: adding 5-98 percent of water for injection into a preparation container, adding propofol phosphate and pharmaceutical salt thereof of 90-110 percent of accurate prescriptions, slowly dropping a pH value regulator while stirring so as to adjust the pH to be 6.0-11, adding water to the full volume, then adding medicinal carbon of 0.01-1.0 percent (W / V), stirring for 15-60 minutes, roughly filtering with a sand filter rod to remove the carbon, and finely filtering with a 0.22mum microporous membrane until the clarity is qualified; and measuring until the intermediate content is acceptable, fixing the filling amount, sub-packaging into cillin bottles, plugging in plugs by half, freezing and drying samples to control the moisture content being 0.1-8 percent, pressing the plugs, and capping.

The present invention is new preparation form of Stepronin, especially Stepronin powder for injection, and its preparation process. The powder for injection consists of Stepronin or its metal salt or amino salt as active component and freeze drying support agent. Compared with available orally taken Stepronin preparation, the present invention has the advantages of high bioavailability, good medicine absorption, fast medicine dispersion, fast acting, etc. The present invention expands the administration range of Stepronin and raises the clinical administration level of Stepronin.

The invention discloses a gambogic acid nano preparation based on a hydrophobic prodrug and capable of improving long circulation. The nano preparation is a gambogic acid prodrug nano preparation andis gambogic acid oleyl alcohol / polyethylene glycol vitamin E succinate nanoparticles. According to the invention, gambogic acid is modified into an inactive prodrug, and the inactive prodrug is administrated in the form of nanoparticles so that the circulating half-life period of gambogic acid in vivo is improved, the vascular irritation during administration is relieved, and the preparation has important theoretical and practical values for clinical application of gambogic acid.

The invention discloses an anti-arrhythmic drug fat emulsion injection and a preparation method thereof. The anti-arrhythmic drug fat emulsion injection is an amiodarone hydrochloride fat emulsion injection which contains amiodarone hydrochloride and a medicinal excipient acceptable pharmaceutically, wherein the medicinal excipient is prepared from an oil phase, an emulsifier, an osmotic pressure regulator, a stabilizing agent, a pH regulator and water for injection. The anti-arrhythmic drug fat emulsion injection is stable in quality and non-irritant to blood vessels, and the security and compliance of clinical drug application are improved.

The present invention belongs to the field of medicine technology, and is especially one kind of medicine composition for treating cardiac and cerebral vascular diseases and its preparations and preparation process. The medicine composition consists of rhodiola root in 300-1800 weight portions, preferably 1000 weight portions, or its extract, and puerarin in 30-500 weight portions, preferably150 weight portions. The composition may be prepared into different pharmaceutically acceptable forms, preferably injection. The composition has synergistic effect and high stability.